Skip to Main Content

Paper Details

Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
JNCI Cancer Spectrum
1
2019
ER, ER+, ESPL1, Early Breast Cancer, EarlyR, EarlyR Gene Signature, EarlyR gene signature, Hormone Receptor, Letrozole, MKI67, PGR, PLK1, RNA, SPAG5, Tamoxifen, Women, breast cancer, estrogen, estrogen receptor, estrogen receptor-positive (ER+) breast cancer, formalin, letrozole, patients, tamoxifen, women
Author NameAffiliation
Meredith M ReganDana Farber Cancer Institute
Meredith M ReganHarvard Medical School
  • 1 - 2

Datasets

Release 1.2